MedTrace Logo

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

NCT03728504 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2023-05-09

Study results available
· View outcomes & findings →

Summary

Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.

Conditions

  • Chronic Hand Dermatitis

Interventions

DRUG

ASN002

Daily dose of ASN002 for 32 weeks

DRUG

Placebo Oral Tablet

Daily dose of Placebo Oral Tablet for 16 weeks

Sponsors & Collaborators

  • Asana BioSciences

    lead INDUSTRY

Principal Investigators

  • David Zammit, Ph.D. · Asana BioSciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-03
Primary Completion
2020-04-29
Completion
2020-04-29
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03728504 on ClinicalTrials.gov